BiVictriX Therapeutics Plc (LON:BVX – Get Free Report)’s share price fell 5.9% during trading on Thursday . The company traded as low as GBX 7.63 ($0.10) and last traded at GBX 8 ($0.11). 127,132 shares were traded during mid-day trading, an increase of 64% from the average session volume of 77,426 shares. The stock had previously closed at GBX 8.50 ($0.11).
BiVictriX Therapeutics Price Performance
The company has a 50-day moving average of GBX 11.41 and a two-hundred day moving average of GBX 11.47. The company has a debt-to-equity ratio of 8.81, a current ratio of 4.40 and a quick ratio of 7.49. The company has a market capitalization of £6.19 million, a PE ratio of -187.50 and a beta of -0.60.
BiVictriX Therapeutics Company Profile
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.
Further Reading
- Five stocks we like better than BiVictriX Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- 3 Fintech Stocks With Good 2021 Prospects
- Why Dell Can Continue Winning in AI and Beyond
- Insider Trading – What You Need to Know
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for BiVictriX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiVictriX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
